Press release
Sjögren’s Syndrome Therapeutics - Pipeline, Key Players Analysis UCB, Bristol-Myers Squibb, Aldeyra Therapeutics
Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.
Download report sample at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample
*Major companies collaborate for the development of Sjögren's syndrome pipeline
The research found that different companies have collaborated for the development of Sjögren’s syndrome.
Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=sjogrens-syndrome-therapeutics-pipeline-analysis
*Positive clinical results of the drug candidates for Sjögren’s syndrome
The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren's syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).
Browse report at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
347 5th Ave. #1402- 210
New York City, NY 10016 United States
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sjögren’s Syndrome Therapeutics - Pipeline, Key Players Analysis UCB, Bristol-Myers Squibb, Aldeyra Therapeutics here
News-ID: 1400042 • Views: …
More Releases from P&S Intelligence
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,…
More Releases for Sjögren
Demand for Autoimmune Disease Diagnostic Products Remains High in North America
Around 3% of the people in the U.S. are affected by autoimmune diseases every year, according to Johns Hopkins University. In such diseases, the immune system malfunctions and starts attacking the healthy cells instead of pathogens. Some of the common autoimmune diseases are celiac disease, lupus, myasthenia gravis, rheumatoid arthritis, Grave’s disease, type 1 diabetes, Guillain–Barre syndrome, multiple sclerosis, and Sjögren syndrome. These diseases are often not treatable, therefore have…
WORLD SJOGREN'S DAY
World Sjögren’s Day - July 23
Chronic fatigue is associated with reduced quality of life
Chronic fatigue is one of the most common symptoms of Sjögren's and clearly differs from the usual fatigue according to Sjögren Europe. “We describe it as an incessant, fluctuating and unreliable lack of vitality that is beyond one's control. Not everyone experiences it the same way, but fatigue is undoubtedly a permanent part of patients'…
Evans Syndrome Market Key Players 2019 - Merck & Co., Sanofi, Astellas Pharma, I …
Market Research Future (MRFR) has announced a new release on the global Evans Syndrome market. The report takes into account the global Evans Syndrome market’s historical growth trajectory and major growth drivers and restraints in order to come up with a reliable projection for the market’s likely growth trajectory over the forecast period from 2018 to 2023.
Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder…
Evans Syndrome Market Growth Boosting Strategies By Top Manufacturers like Pfize …
This report studies the Global Evans Syndrome Market status and outlook of Global Market 2018. The report begins with the overview of Industry Chain structure, and describes industry environment, then analyses market size and...
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as…
Evans Syndrome Market Expected to show Enthralling Growth of 10.2% CAGR by 2023 …
Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5136
According to the Centers for Disease…
Evans Syndrome: Projection of Each Major Segment, Drugs and Treatment over the F …
Market Scenario
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common…
